Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Detection of Bacterial DNA and Collagen Metabolism in Acutely Ruptured Achilles Tendons

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03931486
Recruitment Status : Recruiting
First Posted : April 30, 2019
Last Update Posted : July 14, 2020
Sponsor:
Collaborator:
Bispebjerg Hospital
Information provided by (Responsible Party):
Allan Cramer, Copenhagen University Hospital, Hvidovre

Tracking Information
First Submitted Date April 15, 2019
First Posted Date April 30, 2019
Last Update Posted Date July 14, 2020
Actual Study Start Date May 3, 2019
Estimated Primary Completion Date February 1, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: May 25, 2019)
  • 14C concentration in acutely ruptured Achilles tendons [ Time Frame: The outcome measure will be assesed at time of surgery ]
    14C concentration in biopsies from the ruptured part of the tendons and in the control biopsies proximal to the rupture are compared to the known historical values of atmospheric 14C to estimate the rate of collagen turnover. The values for turnover in the biopsies will be compared to the known rates of turnover in healthy tendons.
  • Heavy water (D2O) enrichment in acutely ruptured Achilles tendons [ Time Frame: The outcome measure will be assesed at time of surgery ]
    2H isotope enrichment in the biopsies from the ruptured part of the tendons and in the control biopsies proximal to the rupture.
  • Fractional synthesis rate of protein at time of surgery in acutely ruptured Achilles tendons. [ Time Frame: The outcome measure will be assesed at time of surgery ]
    The enrichment of the 15N marked proline tracer measured in the biopsies from the ruptured part of the tendons and in the control biopsies and compared to the enrichment of 15N marked proline in the blood. Based on that, the fractional synthesis rate of protein at the time of surgery is calculated.
  • Presence of bacteria in acutely ruptured Achilles tendons. [ Time Frame: The outcome measure will be assesed at time of surgery ]
    Presence of bacterial DNA in the biopsies from the ruptured part of the tendons and in the control biopsies proximal to the rupture detected by 16s rDNA PCR
Original Primary Outcome Measures
 (submitted: April 25, 2019)
  • 14C concentration in acutely ruptured Achilles tendons [ Time Frame: The outcome measure will be assesed at time of surgery ]
    14C concentration in biopsies from the ruptured part of the tendons and in the control biopsies proximal to the rupture are compared to the known historical values of atmospheric 14C to estimate the rate of collagen turnover. The values for turnover in the biopsies will be compared to the known rates of turnover in healthy tendons.
  • Heavy water (D2O) enrichment in acutely ruptured Achilles tendons [ Time Frame: The outcome measure will be assesed at time of surgery ]
    2H isotope enrichment in the biopsies from the ruptured part of the tendons and in the control biopsies proximal to the rupture.
  • Fractional synthesis rate of protein at time of surgery in acutely ruptured Achilles tendons. [ Time Frame: The outcome measure will be assesed at time of surgery ]
    The enrichment of the 13C marked proline tracer measured in the biopsies from the ruptured part of the tendons and in the control biopsies and compared to the enrichment of 13C marked proline in the blood. Based on that, the fractional synthesis rate of protein at the time of surgery is calculated.
  • Presence of bacteria in acutely ruptured Achilles tendons. [ Time Frame: The outcome measure will be assesed at time of surgery ]
    Presence of bacterial DNA in the biopsies from the ruptured part of the tendons and in the control biopsies proximal to the rupture detected by 16s rDNA PCR
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Detection of Bacterial DNA and Collagen Metabolism in Acutely Ruptured Achilles Tendons
Official Title Detection of Bacterial DNA and Collagen Metabolism in Acutely Ruptured Achilles Tendons
Brief Summary

The etiology and pathogenesis of acute Achilles tendon ruptures are complex and not fully understood. It is well known that they are associated with pre-existing pathological alterations, similar to the changes observed in tendinopathy.

The present study investigates if bacteria and collagen metabolism play a role in the etiology of acute Achilles tendon rupture. During surgery, 20 patients will have taken two biopsies from the ruptured part of the tendon and two biopsies from the healthy tissue of the same tendon 2-4 cm proximal to the rupture, as a control.

Detailed Description

Objectives

  1. To investigate the collagen turnover in Achilles tendons prior to a rupture.
  2. To investigate the relative collagen turnover in Achilles tendons the days immediately after a rupture.
  3. To investigate the acute collagen protein synthesis rate in acutely ruptured Achilles tendons.
  4. To investigate if bacterial DNA is present in samples from the degenerative tissue in acutely ruptured Achilles tendons compared with samples from the healthy tissue of the ruptured tendon.

Background

Tendon ruptures are severe injuries that potentially lead to reduced function, reduced activity and sick leave. In younger, sports active individuals with strong tendons, an acute traumatic event is usually needed to trigger a rupture. With age the tendons are exposed to degenerative changes and can therefore rupture in everyday activities (spontaneously).

The etiology and pathogenesis of spontaneous tendon ruptures are complex and not fully understood. It is well known that they are associated with pre-existing pathological alterations, similar to the changes ob-served in tendinopathy. Recently, Dakin et al. found that ruptured Achilles tendons show evidence of chronic (non-resolving) inflammation. The condition might be a result of collagenolytic injury followed by failed tendon healing. Yet, other theories are still highly debated.

Many predisposing factors have been proposed to contribute to the pathological alterations of tendons. Studies found that factors such as increasing age, dominant arm, history of trauma and specific acromial anatomy are associated with rotator cuff tear. It is suggested that spontaneous tendon ruptures, primary Achilles tendon, are related to systemic and injectable steroids, fluoroquinolone use and some rheumatic diseases. Furthermore, studies have shown possible associations between genetic factors and tendon injury. The mentioned factors may influence the initiation and development of the patho-logical alterations that weaken the tendons. However, it is certain there are other mechanisms and predis-posing factors that need to be investigated.

Heinemeier et al. found that the bulk of the collagen matrix of healthy human Achilles tendon core is an essentially permanent structure that is laid down during height growth and has limited turnover in adults. The findings were based on the 14C bomb pulse method, and unpublished data from the same re-search group (using this method) indicates that an abnormally high rate of collagen turnover precedes symptoms of tendon overuse (tendinopathy)It is of great interest to investigate if increased collagen turno-ver predisposes to tendon rupture.

Recently, Rolf et al. demonstrated the presence of bacterial DNA in 25% of samples from ruptured Achilles tendons. Polymerase chain reaction (PCR) was used to identify the highly conserved bacterial 16S rDNA gene in the tendons. This finding open the question, if bacterial depositions play a role in the etiology of spontaneous tendon ruptures In order to prevent tendon ruptures it is essential to improve our understanding of the etiology. A better understanding may also lead to development of new therapeutic options.

In this cross-sectional study, we aim to investigate if bacteria potentially are contributing to the etiology of acute Achilles tendon rupture, Additionally, we also investigate if tendon ruptures are preceded by an in-creased collagen turnover.

Design of the study

The study is conducted as a cross-sectional study. Patients with acute rupture of the Achilles tendon are included The study aims to include 20 patients with acute Achilles tendon rupture.

The procedure for the patient:

  1. At the day of inclusion, the patients will have taken a blood sample and ingest 150ml of deuterium oxide (D2O).
  2. At the day of the surgery, the patient will meet 3 hours before the beginning of the surgery. A bolus of stable isotope (15N marked proline tracer) will be injected and afterwards continuous infused trough the antecubital vein. Blood samples are taken before infusion starts, 30min after, 60min af-ter, 120min after and when the biopsies are taken.
  3. During the surgery, the patients will have taken:

    1. Two biopsies from the stump end of the ruptured tendon or ligament.
    2. Two control biopsies 2-4 cm proximal to the stump end of the ruptured Achilles tendon.

Procedure for biopsies

All biopsies are taken by trained orthopedic surgeons. Every biopsy is taken during surgery in an operating theatre. Before the beginning of the surgery a sterile table is prepared containing three packs of sterile scalpels and forceps, and 8 containers for biopsies with the patient's social security (CPR), the type of analysis and a continues number individually describing each biopsy.

The 8 containers will hold:

  1. Biopsy from the stump end of the ruptured tendon for 16S rDNA analysis.
  2. Biopsy from the stump end of the ruptured tendon for 14C bomb pulse method
  3. Biopsy from the stump end of the ruptured tendon for isotope analysis (deuterium oxide and 15N marked proline).
  4. Biopsy from the stump end of the ruptured tendon for mRNA analysis.
  5. Biopsy from the ruptured tendon 2-4 cm proximal to the stump end for 16S rDNA analysis.
  6. Biopsy from the ruptured tendon 2-4 cm proximal to the stump end for 14C bomb pulse.
  7. Biopsy from the ruptured tendon 2-4 cm proximal to the stump end for isotope analysis (deuterium oxide and 15N marked proline).
  8. Biopsy from the ruptured tendon 2-4 cm proximal to the stump end for mRNA analysis

Biopsies from ruptured tendons

Achilles tendon:

The biopsies are taken during open surgery. To prevent contamination of the biopsies the following proce-dure is followed:

  1. Surgical rub and draping according to normal guidelines.
  2. Skin incision and dissection according to normal guidelines.
  3. As the ruptured tendon is identified, a new pack containing a sterile scalpel and a forceps is opened. The instruments are only used for taking the biopsy and does not get in contact with the surrounding tissue.
  4. 2 biopsies, 10mm long, 1mm broad and 1mm deep, are taken from the degenerated tendon tissue at the rupture site.
  5. The first biopsy is placed in a container (for bacterial detection). On a sterile board, the second bi-opsy is divided in three and placed in three different containers (one for 14C bomb pulse, one for isotope analysis (both deuterium oxide and 15N marked proline) and one for mRNA). These contain-ers are frozen down to -80oC.
  6. A second new pack containing a sterile scalpel and a forceps is opened and 2 biopsies 10 mm long, 1mm broad and 1 mm deep are taken 2-4 cm proximal to the rupture site.
  7. The first biopsy is placed in a container (for bacterial detection) On a sterile board, the second biopsy is divided in three and placed in three different containers (one for 14C bomb pulse, one for isotope analysis (both deuterium oxide and 15N marked proline) and one for mRNA). These contain-ers are frozen down to -80oC.

Contamination tests

PCR and sequencing - Both a negative and a positive control is included in the test. Numbers of cycles in positive samples will also be included in the interpretation. Exclusively environmental bacterial species never been related to human disease are likely to be regarded as contaminants.

Blood culture - During surgery, blood a sample is send for culture to investigate if bacteria were presented in the blood.

Bacterial cultures - Bacterial culture tests are conducted on all patients. The investigated samples are taken with swaps from:

  • Patients skin area over the surgical site.
  • The blade of the used scalpel.

The swaps are collected in separate glass tubes and send to Department of Microbiology, Hvidovre Hospi-tal. The swaps are tested on multiple culture media for multiple species.

Blinding of the analysis

For each included patient, the 2 containers with biopsies for bacterial detection will get a randomized continues number. These numbers can, via a key document (paper form), reveal if the biopsy has been taken from the degenerative tissue or from the healthy tissue. The person responsible for the analyze of the bacterial DNA has no access to the key document.

Data registration during inclusion

  • Patient ID
  • Social security number
  • Phone number
  • Age
  • Weight
  • Date of examination
  • Date and time of insult
  • Corticosteroid injection (number and time)
  • History of infection
Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Cross-Sectional
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
Biopsies from acutely ruptured Achilles tendonds will be taken, Two biopsies from the ruptured part of the tendon and two biopsies from the healthy tissue of the same tendon proximal to the rupture, as a control.
Sampling Method Probability Sample
Study Population Patients diagnosed with acute Achilles tendon rupture, seen in the outpatient clinic at Copenhagen University Hospital, Hvidovre.
Condition Achilles Tendon Rupture
Intervention Not Provided
Study Groups/Cohorts Operatively treated patients with Achilles tendon rupture
Cohort of operatively treated patients with acute Achilles tendon rupture.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: April 25, 2019)
20
Original Estimated Enrollment Same as current
Estimated Study Completion Date July 1, 2022
Estimated Primary Completion Date February 1, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Age 18-70 years
  • Appointment in the Outpatients Department within 4 days after injury.
  • Total Acute Achilles tendon rupture
  • The patient must be able to speak and understand Danish.
  • The patient must be able to give informed consent.

Exclusion Criteria:

  • Rupture of the Achilles tendon either at the insertion on the calcaneus or at musculotendinous junction of the triceps surae.
  • Previous rupture of the same Achilles tendon
  • Undergone any surgery in the same region as the affected Achilles tendon.
  • In medical treatment of diabetes.
  • Present infection in the affected region.
  • Contra-indication for surgery: severe arthrosclerosis with no palpable pulse in the foot, broken skin in the Achilles region of the injured leg.
  • Inability to lie in prone position on the operating table.
  • Rheumatoid arthritis or any other inflammatory disorder of the joints.
  • Terminal illness or severe medical illness. ASA score higher than or equal to 3.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Allan Cramer +4560174294 allancramer94@gmail.com
Listed Location Countries Denmark
Removed Location Countries  
 
Administrative Information
NCT Number NCT03931486
Other Study ID Numbers H-18010363
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: Undecided
Responsible Party Allan Cramer, Copenhagen University Hospital, Hvidovre
Study Sponsor Copenhagen University Hospital, Hvidovre
Collaborators Bispebjerg Hospital
Investigators
Study Chair: Kristoffer W Barfod, MD Copenhagen University Hospital, Hvidovre
PRS Account Copenhagen University Hospital, Hvidovre
Verification Date July 2020